MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma.

被引：0

作者：

Manteca, Maria Victoria Mateos

Grosicki, Sebastian

Kim, Kihyun

Negre, Eric

Vandendries, Erik

机构：

[1] Salamanca Univ Hosp, Salamanca, Spain

[2] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

[3] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[4] Pfizer Inc, Paris, France

[5] Pfizer Inc, Cambridge, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8066

引用

页数：1